What the research made harder to dismiss

The detail I keep returning to is how long people had been suffering.

In a 2023 trial, participants had lived with PTSD for an average of sixteen years. After a program of MDMA-assisted therapy, 71% of those assessed no longer met the diagnostic criteria at eighteen weeks, compared with 48% receiving placebo with the same therapy. The study randomized 104 people; those percentages reflect 52 and 42 assessed participants respectively. [1]

That is a substantial difference, and the improvement in both groups matters. This was a supported treatment program with three drug or placebo sessions. The results describe a particular follow-up, not a permanent cure. Strong drug effects also make it difficult to keep participants unaware of their assignment, complicating how much improvement can be attributed to the drug. [1]

Psilocybin offers another reason to pay attention. In a separate 2023 trial of 104 adults with major depression, one session with psychological support produced greater symptom improvement than niacin placebo across six weeks. Adverse effects were more frequent with psilocybin. [2]

These studies ask different questions, but they both make change worth investigating in places where people may have stopped expecting it.

I had tried a lot of shit. I had put a lot of effort into getting better, and I was getting better. Therapy and earlier experiences had helped. MDMA shifted a remaining piece with a speed and depth that startled me. Reading the research, I found a serious conversation about a possibility I wished I had understood sooner.

Where did the frightening story come from?

An egg in a frying pan can do a remarkable amount of cultural work.

For my mother, the fear around drugs is real. I understand it. If the picture you were handed was brain damage, addiction and a life thrown away, someone talking about healing with those same substances can sound wildly irresponsible.

The famous fried-egg campaign came from the private Partnership for a Drug-Free America. Government messaging had its own history: in 1971, Nixon named drug abuse “America’s public enemy number one,” alongside an announcement covering enforcement, treatment and education. Different institutions helped make “drugs” a single, frightening category. [3, 4]

That category tells us very little about the differences among substances, why someone takes them, or what happens in a carefully supported setting. It also makes a proposed therapeutic use seem like a contradiction before we have even examined it.

Scientific claims can acquire a life of their own, too. A widely discussed 2002 animal study on MDMA was retracted after researchers discovered they had used methamphetamine instead. The correction matters. So does the safety research that remains. [5]

I cannot know how much sooner I might have explored MDMA without those associations. I can see how much they shaped what I was willing to consider, even while I thought of myself as unusually open-minded.

The questions underneath the fear

Would I lose control? Would I feel worse afterward? Could this actually harm me? Those questions deserve useful answers.

Start with the substance. MDMA is an entactogen, associated with emotional openness and connection, rather than a classic psychedelic like psilocybin or LSD. I include it here because I am interested in altered states that may support meaningful therapeutic work. These substances have different effects and risks. [6]

Then consider the setting. A clinical trial uses a known product, screened participants, monitoring and a defined support program. Recreational use can involve uncertain contents, other drugs, heat, exertion and little sleep. Those differences make a party story an imperfect guide to a therapeutic setting. [7]

MDMA itself can still raise heart rate, blood pressure and temperature; serious toxicity is possible. Anxiety, jaw tension and difficult aftereffects are real possibilities. My calm experience adds to that picture without predicting yours. Health conditions and medication interactions need assessment by a qualified clinician. [7]

The emotional experience also varies. Something meaningful may be difficult, confusing or less helpful than expected. The question is how an approach fits a particular person, what support is available, and how problems would be handled. Natural origin cannot answer those questions, any more than a laboratory origin can.

For the fuller evidence, risks and current regulatory status, continue to Understanding MDMA below.

A much older conversation

The modern research can feel startlingly new. The human interest in these states has a much longer history.

In a rock shelter in what is now Bolivia, researchers examined a ritual bundle dating to roughly a thousand years ago. Chemical residues revealed several psychoactive compounds, evidence of botanical knowledge and the movement of plants across regions. The bundle cannot tell us what a ceremony felt like. It does show how far the history reaches beyond the cultural moment most of us associate with psychedelics. [8]

Traditional practices have their own contexts and purposes. Clinical research enters this wider conversation with particular tools: diagnostic criteria, comparison groups, symptom scales and follow-up. Those tools can measure important changes. Spiritual meaning, belonging and a person’s relationship to the world call for other kinds of attention too.

After my MDMA experience, I read something like ninety books. As one does.

Anne Other’s Trust Surrender Receive was especially meaningful. Its accounts of MDMA experiences gave human detail to the clinical questions. I recognized descriptions of emotional material becoming accessible, of people meeting parts of themselves they had struggled to approach. Reading them made my own experience feel less isolated. [9]

Selected accounts cannot tell us how often that happens. They can help us understand what people are trying to describe, and give us better questions to bring back to the research.

The more I learned, the more curious I became about the relationship between these worlds: what can be measured, what can be described, and what an experience may mean to the person living it.

Making an opening part of a life

The newer story has its own temptation: perhaps one extraordinary experience will finally finish the work. When you have been suffering, that possibility can be almost unbearable in its beauty.

I think of these tools as accelerants because of how quickly certain things became possible for me. But an experience happens within a life. There are still relationships, responsibilities, familiar reactions, and mornings when something that felt obvious becomes difficult to remember.

Preparation is a chance to understand what you are bringing: your hopes, fears, expectations, health considerations and support needs. It also leaves room for the possibility that this is not the right approach or the right time.

Integration asks what the experience means in the life you return to. Perhaps you noticed how harshly you speak to yourself. Perhaps a difficult conversation became possible. Perhaps you felt something you had only understood intellectually. The next step might be small and specific: trying a different response, asking for support, or allowing time to understand what remains unsettled.

The MDMA trials involved repeated sessions and substantial support. Their results should not become a promise that one experience will produce the same change. Nor do they establish a universal number of sessions or one best way to integrate. [1]

I value having someone present who can listen closely without deciding what your experience must mean. Someone who can help you notice what is changing, respect what is difficult, and stay interested when the story is more complicated than a breakthrough.

What else might be possible?

I keep returning to that sunset. The laughter was partly about the absurdity of it: I had been warned that I might lose my capacity to enjoy something beautiful, and here I was, more available to it than I could remember being.

That did not settle every question about MDMA. It changed my willingness to ask.

There are real complications in the return of psychedelics: access, cost, regulation, whose knowledge is credited, and who benefits. Those deserve a deeper conversation. So does the possibility that fear and familiarity have kept some of us from examining something that might matter.

You do not need to have an experience to begin learning. Read a study. Listen to an account that surprises you. Ask what a frightening claim rests on, and ask the same of a beautiful promise.

I went looking for relief and found more questions about being human than I had arrived with. I am still following them.

Sources & further reading

1. Mitchell et al. MDMA-assisted therapy for moderate to severe PTSD. Nature Medicine, 2023.

2. Raison et al. Single-dose psilocybin for major depressive disorder. JAMA, 2023.

3. Partnership for Drug-Free Kids. The history of the fried-egg campaign, 2016.

4. Richard Nixon. Remarks on drug abuse prevention and control, June 17, 1971.

5. Ricaurte et al. Retraction of the 2002 MDMA animal study. Science, 2003.

6. David E. Nichols. Entactogens: how the name for a novel class of psychoactive agents came about. Frontiers in Psychiatry, 2022.

7. FDA. MDMA clinical review and safety assessment, 2024.

8. Miller et al. Chemical evidence from a 1,000-year-old ritual bundle in South America. PNAS, 2019.

9. Anne Other. Trust Surrender Receive. Publisher’s description.

Keep exploring

Understanding MDMA
A closer look at the PTSD trials, the experience, risks and current regulatory status.

My Bookshelf
Books on trauma, consciousness and the possibilities that changed how I think about this work.

Preparation and integration support
Space to consider your options and make sense of an experience within the life you are living.